2型神经纤维瘤病患者凸面脑膜瘤的伽玛刀长期疗效
这项国际多中心回顾性研究纳入18例2型神经纤维瘤病(NF2)患者共120个凸面脑膜瘤,分析以伽玛刀放射外科(GKRS)作为初始治疗后的长期结局。中位随访15.6年,仅1例在GKRS后24年出现肿瘤进展,2年、5年、10年无进展生存率均为100%,未见恶性转化或相关死亡。
要点
- GKRS对NF2患者小至中等体积凸面脑膜瘤可提供长期肿瘤控制。
- 中位随访15.6年间仅1例肿瘤进展,未见恶性转化。
- 对需多次治疗的NF2患者,GKRS是微创的确定性治疗选择。
核心结论
- GKRS是NF2患者小至中等体积凸面脑膜瘤安全有效的确定性治疗。
- 尽管这类肿瘤突变负荷特殊,治疗后未见恶性转化。
- GKRS为这一特定患者群体提供微创且长期的肿瘤控制。
研究设计与样本
- 国际多中心回顾性研究,经国际放射外科研究基金会批准。
- 纳入标准为NF2患者、至少1个凸面脑膜瘤且初始GKRS后随访至少6个月。
- 共纳入18例NF2患者、120个凸面脑膜瘤;中位治疗体积0.66 cm3(范围0.10-21.20 cm3)。
- 初始GKRS后中位随访15.6年(范围0.6-25.5年);GKRS时中位年龄32.5岁(范围16-53岁)。
- 每例患者中位脑膜瘤数13个(范围1-27),每例接受GKRS的凸面病灶中位数3.5个(范围1-27)。
主要发现
- 仅1例在GKRS后24年报告肿瘤进展。
- 2年、5年、10年 actuarial 无进展生存率均为100%。
- 未记录到恶性转化,也无因脑膜瘤或放射外科导致的死亡。
临床怎么用
- 对NF2患者的小至中等体积凸面脑膜瘤,可考虑以GKRS作为确定性治疗。
- 长期随访中需关注肿瘤进展,但本研究进展罕见且未见恶性转化。
局限性
- 为回顾性研究,样本量仅18例患者。
- 随访时间范围跨度大(0.6-25.5年),部分患者随访较短。
以上解读依据论文摘要(全文未开放获取或许可不允许翻译转载)。
原文
BACKGROUND: Convexity meningiomas are common tumors requiring treatment in patients with neurofibromatosis type 2 (NF2). Although different therapeutic options are described for sporadic convexity meningioma, much less is known about these lesions in patients with NF2 despite their distinct biology and need for multiple treatments. We analyzed the value of Gamma Knife radiosurgery (GKRS) as definitive treatment for convexity meningiomas in patients with NF2. METHODS: This international multicenter retrospective study was approved by the International Radiosurgery Research Foundation. Patients with NF2 with at least 1 convexity meningioma and 6-month follow-up after primary GKRS were included. RESULTS: Inclusion criteria were met by 18 patients with NF2. A total of 120 convexity meningiomas (median treatment volume, 0.66 cm3 [range, 0.10-21.20 cm3]) were analyzed. Median follow-up after initial GKRS was 15.6 years (range, 0.6-25.5 years). Median age at GKRS was 32.5 years (range, 16-53 years). Median number of meningiomas per patient was 13 (range, 1-27), and median number of convexity lesions receiving GKRS per patient was 3.5 (range, 1-27). One case of tumor progression was reported 24 years after GKRS, leading to actuarial progression-free survival rates of 100% at 2, 5, and 10 years. No malignant transformation or death due to meningioma or radiosurgery was recorded. CONCLUSIONS: GKRS is safe and effective as definitive treatment of small to medium-sized convexity meningiomas in patients with NF2. Despite concerns about the particular mutational burden of these tumors, no malignant transformation manifested after treatment. GKRS represents a minimally invasive option that offers long-term tumor control to this specific group of patients.
引用
- Ruiz-Garcia H, Trifiletti DM, Mohammed N, et al. Convexity Meningiomas in Patients with Neurofibromatosis Type 2: Long-Term Outcomes After Gamma Knife Radiosurgery. World Neurosurg. 2020. PMID: 33152493. doi:10.1016/j.wneu.2020.10.153
供执业医师工作参考,不替代临床判断;数值与分级以指南原文为准。